Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-10-04

Clinical Trial Update: A Study to Test if TV-46000 is Safe for Maintenance Treatment of Schizophrenia [Phase 3]

View source ↗

Summary

Phase 3 trial completed evaluating TV-46000 for maintenance treatment in schizophrenia; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • TV-46000

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Schizophrenia | Phase 3 | Status: COMPLETED | Results posted: 2022-10-04